Amy DuRoss, a director at BioLife Solutions Inc, has reported the sale of 26,857 shares of the company's common stock. This transaction occurred following the completion of a merger with Repligen Corporation on October 6, 2026. The sale is significant as it reflects ongoing consolidation within the electromedical and electrotherapeutic apparatus industry.
The merger, which was finalized under the terms of an agreement dated July 21, 2026, involved the conversion of each outstanding share of BioLife Solutions' common stock into $11.25 in cash and 0.1442 shares of Repligen common stock. This strategic move is expected to reshape the competitive landscape in the industry.
Background
BioLife Solutions Inc, identified by the Central Index Key (CIK) 0000834365, operates within the electromedical and electrotherapeutic apparatus sector. The company is incorporated in Delaware and has its business address in Bothell, Washington. Recent filings indicate that DuRoss has been actively managing her shareholdings, with this transaction being part of a series of filings dating back to early 2026.
What the Filing Says
The filing details that DuRoss disposed of 26,857 shares on October 6, 2026, following the merger. According to the filing, "Reflects the disposition of shares of common stock of BioLife Solutions, Inc. in connection with the consummation on October 6, 2026 of the merger..." This indicates a significant change in her ownership position within the company.
Impact
This transaction may affect various stakeholders, including other shareholders of BioLife Solutions and Repligen Corporation. The merger is likely to influence the strategic direction of both companies and could lead to further consolidation in the electromedical sector.
What's Next
The filing does not say what happens next.